Citations

Clear

7551 citation(s) found for "Ho, Matthew".

Effect of Disease Activity, Glucocorticoid Exposure, and Rituximab on Body Composition During Induction Treatment of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis
Wallace, Zachary S. , Miloslavsky, Eli M. , Cascino, Matthew D., Unizony, Sebastian , Lu, Na , Hoffman, Gary S., Kallenberg, Cees G. M., Langford, Carol A. , Clair, E. William St. , Brunetta, Paul , Stone, John H. , Merkel, Peter A. , Monach, Paul A. , Seo, Philip , Spiera, Robert , Specks, Ulrich , Choi, Hyon K.

Mayo Clinic

Arthritis Care & Research | October 7, 2016 | Volume: 69 | Issue: 7 | Pages: 1004-1010

10.1002/acr.23099 | PMID 27696762 Get It

ObjectiveWe investigated the relationships between glucocorticoid use, disease activity, and changes in body mass index (BMI) in patients with antineutrophil cytoplasmic antibody–associated vasculitis (AAV).MethodsWe analyzed AAV patients enrolled in the Rituximab in AAV trial. Glucocorticoid use, BMI, and disease activity were measured regularly during the trial period. We performed mixed‐effects regressions to examine the associations of time‐dependent cumulative average glucocorticoid use and disease activity with changes in BMI over time, while adjusting for potential confounders.ResultsThe mean ± SD baseline BMI of the 197 patients enrolled was 28.8 ± 6.3 kg/m2. Patients with newly diagnosed AAV tended to have a lower mean ± SD BMI than those with relapsing disease (28.0 ± 5.7 kg/m2 versus 29.6 ± 6.8 kg/m2) and higher disease activity (mean ± SD Birmingham Vasculitis Activity Score for Wegener's Granulomatosis 8.7 ± 3.3 versus 7.4 ± 2.7). The most significant change in BMI occurred during the first 6 months of the trial (mean ± SD increase of 1.1 ± 2.2 kg/m2; P < 0.0001). Disease activity improvement, glucocorticoid exposure, and randomization to rituximab were each independently associated with an increase in BMI (P < 0.001 for all analyses).ConclusionOur findings suggest that changes in BMI, as well as glucocorticoid exposure, are independently associated with improvements in disease activity in AAV. Rituximab may also have effects on BMI independent of its impact on disease activity.
Defining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, Clifford R. , Wiste, Heather J. , Weigand, Stephen D. , Therneau, Terry M. , Lowe, Val J. , Gunter, Jeffrey L. , Senjem, Matthew L. , Kantarci, Kejal , Mielke, Michelle M. , Roberts, Rosebud O., Vemuri, Prashanthi , Reyes, Denise A., Petersen, Ronald C. , Knopman, David S. , Jones, David T. , Machulda, Mary M. , Jack, Clifford R , Mielke, Michelle M , Vemuri, Prashanthi , Senjem, Matthew L , Kantarci, Kejal

Mayo Clinic

Alzheimer's & Dementia | October 5, 2016 | Volume: 13 | Issue: 3 | Pages: 205-216

10.1016/j.jalz.2016.08.005 | PMID 27697430 Get It

Abstract Introduction Our goal was to develop cut points for amyloid positron emission tomography (PET), tau PET, flouro‐deoxyglucose (FDG) PET, and MRI cortical thickness. Methods We examined five methods for determining cut points. Results The reliable worsening method produced a cut point only for amyloid PET. The specificity, sensitivity, and accuracy of cognitively impaired versus young clinically normal (CN) methods labeled the most people abnormal and all gave similar cut points for tau PET, FDG PET, and cortical thickness. Cut points defined using the accuracy of cognitively impaired versus age‐matched CN method labeled fewer people abnormal. Discussion In the future, we will use a single cut point for amyloid PET (standardized uptake value ratio, 1.42; centiloid, 19) based on the reliable worsening cut point method. We will base lenient cut points for tau PET, FDG PET, and cortical thickness on the accuracy of cognitively impaired versus young CN method and base conservative cut points on the accuracy of cognitively impaired versus age‐matched CN method.
Experiences of long-term life-limiting conditions among patients and carers: what can we learn from a meta-review of systematic reviews of qualitative studies of chronic heart failure, chronic obstructive pulmonary disease and chronic kidney disease?
May, Carl , Cummings, Amanda , Myall, Michelle , Harvey, J Matthew , Pope, Catherine , Griffiths, Peter , Roderick, Paul , Arber, Mick , Boehmer, Kasey R. , Mair, Frances S , Boehmer, Kasey, Richardson, Alison Mead

Mayo Clinic

BMJ Open | October 5, 2016 | Volume: 6 | Issue: 10 | Pages: e011694

10.1136/bmjopen-2016-011694 | PMID 27707824 Get It

Objectives To summarise and synthesise published qualitative studies to characterise factors that shape patient and caregiver experiences of chronic heart failure (CHF), chronic obstructive pulmonary disease (COPD) and chronic kidney disease (CKD). Design Meta-review of qualitative systematic reviews and metasyntheses. Papers analysed using content analysis. Data sources CINAHL, EMBASE, MEDLINE, PsychINFO, Scopus and Web of Science were searched from January 2000 to April 2015. Eligibility criteria for selecting studies Systematic reviews and qualitative metasyntheses where the participants were patients, caregivers and which described experiences of care for CHF, COPD and CKD in primary and secondary care who were aged ≥18 years. Results Searches identified 5420 articles, 53 of which met inclusion criteria. Reviews showed that patients' and caregivers' help seeking and decision-making were shaped by their degree of structural advantage (socioeconomic status, spatial location, health service quality); their degree of interactional advantage (cognitive advantage, affective state and interaction quality) and their degree of structural resilience (adaptation to adversity, competence in managing care and caregiver response to demands). Conclusions To the best of our knowledge, this is the first synthesis of qualitative systematic reviews in the field. An important outcome of this overview is an emphasis on what patients and caregivers value and on attributes of healthcare systems, relationships and practices that affect the distressing effects and consequences of pathophysiological deterioration in CHF, COPD and CKD. Interventions that seek to empower individual patients may have limited effectiveness for those who are most affected by the combined weight of structural, relational and practical disadvantage identified in this overview. We identify potential targets for interventions that could address these disadvantages. Systematic review registration number PROSPERO CRD42014014547.
Prevalence and Surgical Implications of Dural Enhancement at the Porus Acusticus in Vestibular Schwannomas
Patel, Neil , Abel, Kathryn M. Van , Link, Michael J. , Driscoll, Colin L. W., Neff, Brian A., Lane, John I. , Carlson, Matthew L. , Van Abel, Kathryn M, Van Gompel, Jamie J, Gompel, Jamie J. Van , Van Abel, Kathryn M

Mayo Clinic

Otolaryngology–Head and Neck Surgery | October 4, 2016 | Volume: 155 | Issue: 6 | Pages: 1021-1027

10.1177/0194599816670144 | PMID 27703093 Get It

ObjectiveDemonstrate the association of radiographic dural enhancement with increased tumor adherence at the porus acusticus, which may influence completeness of resection and facial nerve outcome.Study DesignCase series with chart review.SettingAcademic referral center.Subjects and MethodsA total of 205 consecutive patients with histopathologically confirmed vestibular schwannoma (VS) were evaluated. Patients with tumors exhibiting dural enhancement on postgadolinium T1‐weighted magnetic resonance imaging were identified and compared with matched controls. Completeness of resection, intraoperative details, and facial nerve outcomes were analyzed.ResultsExcluding strictly intracanalicular tumors (n = 32, 16%) and those with NF2 (n = 10, 4.9%), the presence of dural enhancement was radiographically confirmed in 16 (9.8%) cases. Paired analysis did not reveal significant baseline differences between cases and controls. Subtotal resection was performed in 5 (31%) of the 16 patients with tumors exhibiting dural enhancement, in contrast to 1 (3%) of the matched controls (P =. 01). Four (25%) demonstrated increased tumor adherence at the porus acusticus intraoperatively, compared with 1 control (3%, P =. 04). Long‐term facial nerve function was similar between cases and controls (81% vs 84% House‐Brackmann I‐II function, P = 1.00).ConclusionDural enhancement is present in approximately 10% of extracanalicular VS. Dural enhancement at the porus acusticus may represent hypervascularity, dural reaction, or infiltration, and portends increased tumor adherence and greater likelihood of subtotal resection to preserve facial nerve function. To our knowledge, this is the first series that reports the prevalence of this phenomenon in VS and the potential surgical implications. Recognition preoperatively may be valuable toward patient counseling.
What Factors Influence the Outcome of Surgically Treated Soft Tissue Sarcomas of the Hand and Wrist?
Wilke, Benjamin K. , Rose, Peter S. , Walczak, Brian E, Houdek, Matthew T. , Walczak, Brian E. , Kakar, Sanjeev , Shin, Alexander Y. , Wilke, B K

Mayo Clinic

HAND | October 3, 2016 | Volume: 12 | Issue: 5 | Pages: 493-500

10.1177/1558944716672197 | PMID 28832212 Get It

Background: Soft tissue sarcomas (STS) of the hand are exceedingly rare. The aim of this study was to review our institution’s experience with STS of the hand to identify factors affecting outcomes and survivorship. Methods: We retrospectively reviewed the records of 46 hand STS treated with definitive surgery at our institution between 1992 and 2013. Pertinent demographics as well as information regarding the surgical procedure, and disease status at latest follow-up were reviewed. Mean age at diagnosis was 38 years with a mean follow-up of 5 years. Results: The most common tumor subtypes were epithelioid (n = 10) and synovial sarcoma (n = 8). Sixty-one percent were superficial in location. Thirty-three patients had had a nononcologic resection prior to definitive surgical treatment at our institution. Ultimately, negative margins were obtained in all cases. Local recurrence was observed in 5 patients and distant metastases in 14 patients. Tumor sizes ≥2 cm, American Joint Committee on Cancer (AJCC) grade, and depth of the tumor were found to adversely affect the outcome in terms of disease-free and overall survival. Reexcision of an inadvertently excised tumor at an outside institution did not adversely affect the outcome. The 10-year overall and disease-free survival was 72% and 63%. Conclusions: Local recurrence after a wide excision was observed infrequently; however, distant disease was relatively common. Tumors with a size ≥2 cm were associated with a worse disease-free and overall survival, highlighting the aggressive nature of these tumors.
Safety and Efficacy of Extended Duration of Thromboembolic Prophylaxis Following Radical Cystectomy: An Initial Institutional Experience
Zaid, Harras B. , Yang, David Y. , Tollefson, Matthew K. , Frank, Igor, Parker, William P. , Thompson, R. Houston, Karnes, R. Jeffrey , Boorjian, Stephen A. , Yang Md, David

Mayo Clinic

Urology Practice | September 30, 2016 | Volume: 3 | Issue: 6 | Pages: 462-467

10.1016/j.urpr.2016.01.002 | PMID 37592606 Get It

Sex Differences and Survival in Adults With Bicuspid Aortic Valves: Verification in 3 Contemporary Echocardiographic Cohorts
Suri, Rakesh M. , Katan, Ognjen, Eleid, Mackram F. , Clavel, Marie‐Annick , Pellikka, Patricia A. , Enriquez‐Sarano, Maurice , Maurer, Mathew J, Mahoney, Douglas, Michelena, Héctor I. , Maurer, Matthew J. , Mahoney, Douglas W. , Pellikka, Patricia A , Enriquez-Sarano, Maurice , Clavel, Marie-Annick

Mayo Clinic

Journal of the American Heart Association | September 30, 2016 | Volume: 5 | Issue: 10 | Pages: No page available

10.1161/jaha.116.004211 | PMID 27688238 Get It

Background Sex‐related differences in morbidity and survival in bicuspid aortic valve (BAV) adults are fundamentally unknown. Contemporary studies portend excellent survival for BAV patients identified at early echocardiographic‐clinical stages. Whether BAV adults incur a survival disadvantage throughout subsequent echocardiographic‐clinical stages remains undetermined. Methods and Results Analysis was done of 3 different cohorts of consecutive patients with echocardiographic diagnosis of BAV identified retrospectively: (1) a community cohort of 416 patients with first BAV diagnosis (age 35±21 years, follow‐up 16±7 years), (2) a tertiary clinical referral cohort of 2824 BAV adults (age 51±16 years, follow‐up 9±6 years), and (3) a surgical referral cohort of 2242 BAV adults referred for aortic valve replacement (AVR) (age 62±14 years, follow‐up 6±5 years). For the community cohort, 20‐year risks of aortic regurgitation (AR), AVR, and infective endocarditis were higher in men (all P ≤0.04); for a total BAV‐related morbidity risk of 52±4% vs 35±6% in women ( P =0.01). The cohort's 25‐year survival was identical to that in the general population ( P =0.98). AR independently predicted mortality in women ( P =0.001). Baseline AR was more common in men ( P ≤0.02) in the tertiary cohort, with 20‐year survival lower than that in the general population ( P <0.0001); age‐adjusted relative death risk was 1.16 (95% confidence interval [CI] 1.05‐1.29) for men versus 1.67 (95% CI 1.38‐2.03) for women ( P =0.001). AR independently predicted mortality in women ( P =0.01). Baseline AR and infective endocarditis were higher in men (both ≤0.001) for the surgical referral cohort, with 15‐year survival lower than that in the general population ( P <0.0001); age‐adjusted relative death risk was 1.34 (95% CI 1.22‐1.47) for men versus 1.63 (95% CI 1.40‐1.89) for women ( P =0.026). AR and NYHA class independently predicted mortality in women (both P ≤0.04). Conclusions Within evolving echocardiographic‐clinical stages, the long‐term survival of adults with BAV is not benign, as both men and women incur excess mortality. Although BAV‐related morbidity is higher in men in the community, and AR and infective endocarditis are more prevalent in men, women exhibit a significantly higher relative risk of death in tertiary and surgical referral cohorts, which is independently associated with AR.
Safety of Intra-Articular Implantation of Oligo[Poly(ethylene glycol) Fumarate] Scaffolds into the Rabbit Knee
Ewald, Timothy J., Walker, Justin A. , Lewallen, Eric A. , Trousdale, William H. , Yaszemski, Michael J. , Hanssen, Arlen D. , Morrey, B.F. , Wijnen, André J. van , Morrey, Bernard F, van Wijnen, Andre J, Sanchez-Sotelo, Joaquin, Sánchez‐Sotelo, Joaquín , Morrey, Mark E. , Abdel, Matthew P. , van Wijnen, Andre J

Mayo Clinic

Tissue Engineering Part C: Methods | September 27, 2016 | Volume: 22 | Issue: 10 | Pages: 991-998

10.1089/ten.tec.2016.0209 | PMID 27673559 Get It

Knowledge Gaps in Cardiovascular Care of Older Adults: A Scientific Statement from the American Heart Association, American College of Cardiology, and American Geriatrics Society: Executive Summary
Rich, Michael W. , Chyun, Deborah , Skolnick, Adam H. , Kitzman, Dalane W. , McClurken, James B., Shen, Win K., Tirschwell, David , Alexander, Karen P. , Forman, Daniel E. , Maurer, Matthew J. , Resnick, Barbara M.

Mayo Clinic

Journal of the American Geriatrics Society | September 27, 2016 | Volume: 64 | Issue: 11 | Pages: 2185-2192

10.1111/jgs.14576 | PMID 27673575 Get It

The incidence and prevalence of most cardiovascular disorders increase with age, and cardiovascular disease ( CVD ) is the leading cause of death and major disability in adults aged 75 and older. Despite the effect of CVD on quality of life, morbidity, and mortality in older adults, individuals aged 75 and older have been markedly underrepresented in most major cardiovascular trials, and virtually all trials have excluded older adults with complex comorbidities, significant physical or cognitive disabilities, frailty, or residence in nursing homes and assisted living facilities. As a result, current guidelines are unable to provide evidence‐based recommendations for diagnosis and treatment of older adults typical of those encountered in routine clinical practice. The objectives of this scientific statement are to summarize current guideline recommendations as they apply to older adults, identify critical gaps in knowledge that preclude informed evidence‐based decision‐making, and recommend future research to close existing knowledge gaps. To achieve these objectives, a detailed review was conducted of current American College of Cardiology/American Heart Association ( ACC / AHA ) and American Stroke Association ( ASA ) guidelines to identify content and recommendations that explicitly targeted older adults. A pervasive lack of evidence to guide clinical decision‐making in older adults with CVD was found, as well as a paucity of data on the effect of diagnostic and therapeutic interventions on outcomes that are particularly important to older adults, such as quality of life, physical function, and maintenance of independence. Accordingly, there is a critical need for a multitude of large population‐based studies and clinical trials that include a broad spectrum of older adults representative of those seen in clinical practice and that incorporate relevant outcomes important to older adults in the study design. The results of these studies will provide the foundation for future evidence‐based guidelines applicable to older adults and enhance person‐centered care of older individuals with CVD in the United States and around the world.
Treatment of eosinophilic otitis media with pegylated interferon‐α 2a and 2b
Neff, Brian A., Voss, Stephen G. , Carlson, Matthew L. , O’Brien, Erin K. , Butterfield, Joseph H. , O'Brien, Erin K

Mayo Clinic

The Laryngoscope | September 26, 2016 | Volume: 127 | Issue: 5 | Pages: 1208-1216

10.1002/lary.26303 | PMID 27667784 Get It

Objective/HypothesisEosinophilic otitis media (EOM) is a variant of chronic otitis media that is characterized by the development of thick mucoid middle ear effusion, adult onset bronchial asthma, sinonasal polyposis, and aspirin sensitivity. EOM is typically refractory to corticosteroid therapy and surgical intervention. Pegylated interferon (PEG‐IFN) has effectively treated hypereosinophilic syndrome in clinical trials; however, the efficacy of this medication for EOM treatment remains undefined.Study DesignRetrospective, case series, tertiary academic center.MethodsA retrospective chart review was performed on EOM patients from 2008–2014. A total of 32 patients met the clinical criteria for EOM according to established diagnostic guidelines. Outcomes of all patients with severe, refractory EOM who initiated PEG‐IFN therapy are reported.ResultsEight patients were treated with pegylated interferon‐α 2a or 2b for refractory EOM. Half of the patients had significant side effects with interferon treatment. Three of these were able to continue at a reduced dosage without side effect reoccurrence, and one patient stopped the medication permanently. Four of eight (50%) patients had a complete clinical response with total resolution of otorrhea and normalization of middle ear mucosa, and were able to discontinue corticosteroid treatment. Two patients attempted to stop PEG‐IFN therapy after prolonged symptom remission and had recurrent otorrhea. Both patients had symptom resolution after PEG‐IFN reinitiation.ConclusionsThese data demonstrate that pegylated interferon‐α 2a and 2b therapy may benefit patients with severe, refractory EOM. Further larger studies with long‐term follow‐up are required to validate these early but promising results.Level of Evidence4. Laryngoscope, 127:1208–1216, 2017